Employees: 5,221
Size Luye Pharma (2186.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $736M, the 657th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$1.54 on 18 Nov 2026.
Performance Over six months the shares fell 32.5%, against -7.3% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 3rd lowest of 20 in its peer set.
Growth Revenue grew 2.8% over the last twelve months (peer median +3.5%); the operating margin is 18.5% (peer median 8.8%).
Valuation It trades at 7.1× forward earnings against a peer median of 16.1× (cheapest of 6).
Price implies For today's price to make sense, revenue must grow about -12% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is -14 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 2.0 points below its cost of capital (6.8% WACC).
Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$6.85B | HK$6.84B | HK$6.57B | HK$6.79B | HK$6.96B |
| Revenue growth | — | +4% | -3% | -2% | — |
| Gross profit | HK$4.36B | HK$4.51B | HK$4.38B | HK$4.64B | HK$4.81B |
| EBITDA | HK$2.23B | HK$2.27B | HK$2.11B | HK$1.79B | HK$1.82B |
| Net income | HK$780M | HK$671M | HK$512M | HK$589M | HK$703M |
| Free cash flow | HK$1.17B | HK$1.59B | -HK$493M | HK$1.04B | HK$1.72B |
| Capital expenditure | HK$749M | HK$1.09B | HK$1.85B | HK$1.29B | HK$1.35B |
| Total debt | n/a | HK$10.5B | HK$11.0B | HK$9.27B | HK$10.2B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 2186.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.6% | -2.4% | 6th lowest of 20 |
| 6-month return | -32.5% | -7.3% | 3rd lowest of 20 |
| Distance from 52-week high | -52.6% | -33.7% | 3rd lowest of 20 |
| Revenue growth (TTM) | +2.8% | +3.5% | 9th lowest of 19 |
| Operating margin | 18.5% | 8.8% | 4th highest of 19 |
| Forward P/E | 7.1× | 16.1× | cheapest of 6 |
| Growth the price implies (Req g, 7 yrs) | -11.8% | 4.0% | least demanding of 12 |
| Growth delivered (Del g) | +1.9% | +0.5% | 6th highest of 12 |
| Hurdle (Req g minus delivered) | -13.7 pp | -1.4 pp | 2nd least demanding of 12 |
| ROIC minus cost of capital | -2.0 pp | +0.4 pp | 4th lowest of 17 |
| EV / EBITDA | 3.4× | 8.3× | cheapest of 5 |
| Net debt / EBITDA | -0.2× | -1.2× | 2nd most indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Luye Pharma 2186.HK | Hong Kong | $736M | -32% | +3% | 18% | 7.1× | -11.8% | +1.9% |
| Hunan Jiudian Pharmaceutical 300705.SZ | China | $738M | -20% | -5% | 13% | 16.7× | -2.0% | +26.1% |
| Jiangsu Jibeier Pharmaceutical 688566.SS | China | $727M | -9% | +8% | 26% | 11.2× | 5.9% | +11.3% |
| Shanghai Jiaoda Onlly 600530.SS | China | $726M | -25% | -2% | -2% | n/a | 42.7% | -0.9% |
| Zhuzhou Qianjin Pharmaceutical 600479.SS | China | $746M | -3% | +4% | 11% | n/a | -2.1% | 0.0% |
| Hunan Warrant Pharmaceutical 688799.SS | China | $725M | -34% | -3% | 9% | 47.6× | n/a | n/a |
| Sagimet Biosciences SGMT | United States | $722M | +52% | n/a | n/a | n/a | n/a | n/a |
| CARsgen Therapeutics 2171.HK | Hong Kong | $751M | -45% | +68% | -170% | n/a | n/a | n/a |
| Chongqing Pharscin Pharmaceutical 002907.SZ | China | $752M | -7% | +8% | 10% | n/a | 9.4% | -1.4% |
| Hunan Fangsheng Pharmaceutical 603998.SS | China | $719M | -1% | +12% | 20% | 13.7× | -4.8% | +6.4% |
| Guizhou Bailing Group Pharmaceutical 002424.SZ | China | $755M | -20% | -25% | 2% | n/a | 13.5% | -0.2% |
| China Traditional Chinese Medicine 0570.HK | Hong Kong | $716M | -31% | -16% | 0% | n/a | n/a | n/a |
| Mochida Pharmaceutical 4534.T | Japan | $714M | -3% | +16% | 10% | 16.1× | n/a | n/a |
| Katakura Industries 3001.T | Japan | $765M | +40% | -2% | 15% | n/a | 0.3% | +0.5% |
| Lexicon Pharmaceuticals LXRX | United States | $766M | -22% | -46% | -147% | n/a | n/a | n/a |
| Guizhou Xinbang Pharmaceutical 002390.SZ | China | $771M | -7% | -13% | 4% | n/a | -3.8% | -0.8% |
| HPGC Renmintongtai Pharmaceutical 600829.SS | China | $701M | -6% | +4% | 2% | n/a | 4.0% | +5.3% |
| Nuvectis Pharma NVCT | United States | $698M | +91% | n/a | n/a | n/a | n/a | n/a |
| Bliss GVS Pharma BLISSGVS.NS | India | $777M | +141% | +25% | 18% | n/a | 33.9% | +10.1% |
| Sichuan Neautus Traditional Chinese 2206.HK | Hong Kong | $779M | n/a | +7% | 8% | n/a | n/a | n/a |
| Zhejiang Int'l 000411.SZ | China | $783M | -21% | +3% | 3% | n/a | n/a | n/a |